A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer

SIMPLE SUMMARY: Today, clinical management for the majority of cancer patients is still based on a “one-size-fits-all” approach. To improve the outcomes in the era of personalized medicine, it is essential to stratify patients based on established and novel biomarkers. In the present study, we inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfohl, Ulrike, Loskutov, Jürgen, Bashir, Sanum, Kühn, Ralf, Herter, Patrick, Templin, Markus, Mamlouk, Soulafa, Belanov, Sergei, Linnebacher, Michael, Bürtin, Florian, Vetter, Marcus, Reinhard, Christoph, Wedeken, Lena, Regenbrecht, Christian R. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265111/
https://www.ncbi.nlm.nih.gov/pubmed/35805024
http://dx.doi.org/10.3390/cancers14133252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265111/
https://www.ncbi.nlm.nih.gov/pubmed/35805024
http://dx.doi.org/10.3390/cancers14133252

Ejemplares similares